New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2013
11:24 EDTMDT, ABT, PFE, BSX, JNJPatent ruling disputed by J&J, Pfizer upheld on appeal
Pfizer's (PFE) Wyeth and Johnson & Johnson's (JNJ) Cordis units appealed a lower court opinion that certain patent claims related to the use of rapamycin for the treatment and prevention of the renarrowing of an artery are invalid. An appeals court upheld the lower court ruling in favor of defendants Abbott (ABT), Medtronic (MDT) and Boston Scientific (BSX). Reference Link
News For ABT;JNJ;PFE;MDT;BSX From The Last 14 Days
Check below for free stories on ABT;JNJ;PFE;MDT;BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 10, 2014
16:32 EDTMDTMedtronic gets FDA approval for revised labeling application
The U.S. FDA approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators, expanding the indication for use to patients with atrioventricular block and less severe heart failure. The FDA previously approved these devices for patients with more severe heart failure as evaluated by their physician using specific criteria. The new approved use includes patients with less severe heart failure, but who are already indicated to receive RV pacing. With the new indication, these patients will be eligible to receive a device that will pace both sides of their heart instead of just the right. Reference Link
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
April 9, 2014
11:43 EDTABTGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTJNJEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
April 8, 2014
11:03 EDTPFEPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
07:26 EDTMDT, JNJElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
18:01 EDTBSXBoston Scientific gets FDA, CE Mark clearance for Expect Slimline Needle
Boston Scientific announced it has received clearance from the U.S. FDA and CE Mark approval in Europe for the Expect Slimline Needle, which is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration procedures. The Expect Slimline Needle is on contract with four leading group purchasing organizations.
17:28 EDTPFEPfizer sell-off unwarranted, Barron's says
Subscribe for More Information
16:28 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
12:15 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTPFEPfizer trades near lows of the day, levels to watch
Subscribe for More Information
09:10 EDTPFEOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:09 EDTPFEConfusion on Pfizer Palbo could create buying opportunity, says BMO Capital
Subscribe for More Information
09:00 EDTPFEPfizer falls 2.8%
Pfizer is down 2.8%, or 90c, to $31.25
07:58 EDTMDTMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTMDTMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
07:27 EDTPFEAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
April 6, 2014
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use